SCHEMBL5540424

SCHEMBL5540424

[O]c1cccc2c1oc1ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 4/20 0.47
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 5/20 0.46
MAPT P10636 2/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GLA P06280 1/20 0.46
CYP3A4 P08684 1/20 0.46
PGAM1 P18669 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
HSD17B10 Q99714 1/20 0.46
ALOX5 P09917 3/20 0.46
AHR P35869 3/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
LMNA P02545 1/20 0.43
KDM5A P29375 1/20 0.42
PIK3CD O00329 1/20 0.41
PIK3CB P42338 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13564032 0.79 AHR (0.52) MAOAKDM4EALDH1A1MAPTHPGD
SCHEMBL1635471 0.79 AHR (0.52) MAOAKDM4EALDH1A1MAPTHPGD
SCHEMBL10945864 0.77 ALOX5 (0.68) MAOAKDM4EALDH1A1MAPTHPGD
SCHEMBL12996513 0.76 ALOX5 (0.66) MAOAKDM4EALDH1A1MAPTHPGD
SCHEMBL431458 0.76 ALOX5 (0.66) MAOAKDM4EALDH1A1MAPTHPGD
SCHEMBL430138 0.76 ALOX5 (0.66) MAOAKDM4EALDH1A1MAPTHPGD
SCHEMBL56942 0.76 MAOA (0.54) MAOAKDM4EALDH1A1MAPTHPGD
SCHEMBL5028273 0.76 ALOX5 (0.66) MAOAKDM4EALDH1A1MAPTHPGD
SCHEMBL23046767 0.75 ALOX5 (0.44) MAOAKDM4EALDH1A1MAPTHPGD
SCHEMBL15074808 0.74 ALOX5 (0.46) MAOAKDM4EALDH1A1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAOA 2885/4885KDM4E 4854/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.